NWA
SNDX icon

Navis Wealth Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Navis Wealth Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,000
Closed -$133K – 172
2020
Q4 		$133K Buy
+6,000
New +$124K 0.12% 101

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Navis Wealth Advisors's SNDX Position: Q1 2021 in Review

Navis Wealth Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2021, closing a stake of 6,000 shares — an estimated $133K sold.

Navis Wealth Advisors first reported a position in SNDX in Q4 2020 and held it in 1 quarter. The position peaked at $133K in Q4 2020. 130 funds tracked by Wall St. Rank hold SNDX as of Q1 2021.

  • Navis Wealth Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Navis Wealth Advisors sold 6,000 Syndax Pharmaceuticals shares in Q1 2021, an estimated $133K.
  • Navis Wealth Advisors first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Navis Wealth Advisors's Syndax Pharmaceuticals position peaked at $133K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2021.

Based on Navis Wealth Advisors's 13F filing for Q1 2021, filed 18 May 2021.